We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-7.21%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.1B
AUM Growth
-$504M
Cap. Flow
-$227M
Cap. Flow %
-10.82%
Top 10 Hldgs %
55.38%
Holding
76
New
4
Increased
13
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$39M
2
BSX icon
Boston Scientific
BSX
+$20.1M
3
BHVN icon
Biohaven
BHVN
+$10.8M
4
RGNX icon
Regenxbio
RGNX
+$9.92M
5
EVH icon
Evolent Health
EVH
+$7M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$68.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$42.4M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.4M
4
FOLD
Amicus Therapeutics
FOLD
+$33.8M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.1%
2 Industrials 3.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
26
Kymera Therapeutics
KYMR
$9.1B
$26M 1.24%
1,868,507
– –
SYK icon
27
Stryker
SYK
$127B
$25.9M 1.23%
94,738
+8,839
+10% +$2.53M
IGMS
28
DELISTED
IGM Biosciences
IGMS
$24.8M 1.18%
2,971,542
– –
DXCM icon
29
DexCom
DXCM
$27.6B
$22.8M 1.08%
244,391
-44,770
-15% -$5.05M
NRIX icon
30
Nurix Therapeutics
NRIX
$2.43B
$22.4M 1.07%
2,848,827
-8,482
-0.3% -$77.4K
TRDA icon
31
Entrada Therapeutics
TRDA
$227M
$20.3M 0.97%
1,284,000
-27,572
-2% -$434K
COGT icon
32
Cogent Biosciences
COGT
$6.79B
$20M 0.95%
2,053,333
– –
STOK icon
33
Stoke Therapeutics
STOK
$1.82B
$15.3M 0.73%
3,872,696
-82,492
-2% -$542K
GRTS
34
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$14.6M 0.7%
8,509,126
+1,648,900
+24% +$2.93M
XENE icon
35
Xenon Pharmaceuticals
XENE
$6.32B
$14.3M 0.68%
419,568
-700,908
-63% -$26.2M
BHVN icon
36
Biohaven
BHVN
$2.16B
$13.5M 0.64%
+518,924
New +$10.8M
CRL icon
37
Charles River Laboratories
CRL
$10.9B
$13M 0.62%
66,382
-47,969
-42% -$9.85M
ADCT icon
38
ADC Therapeutics
ADCT
$146M
$12.7M 0.61%
14,178,045
+128,110
+0.9% +$170K
EVH icon
39
Evolent Health
EVH
$475M
$12.7M 0.6%
465,282
+251,850
+118% +$7M
PRME icon
40
Prime Medicine
PRME
$533M
$12.6M 0.6%
1,324,350
– –
ETNB
41
DELISTED
89bio
ETNB
$11.8M 0.56%
761,955
– –
VERV
42
DELISTED
Verve Therapeutics
VERV
$10.7M 0.51%
809,777
-252,183
-24% -$4.06M
ABSI icon
43
Absci
ABSI
$1.28B
$10.6M 0.5%
8,031,094
– –
ALLK
44
DELISTED
Allakos
ALLK
$9.39M 0.45%
4,135,061
+1,851,467
+81% +$6.87M
ATRA icon
45
Atara Biotherapeutics
ATRA
$71.2M
$9.3M 0.44%
251,233
+9,308
+4% +$414K
STXS icon
46
Stereotaxis
STXS
$129M
$9.11M 0.43%
5,765,792
-608,106
-10% -$973K
STTK icon
47
Shattuck Labs
STTK
$710M
$8.54M 0.41%
5,619,914
– –
ANNX icon
48
Annexon
ANNX
$855M
$8.27M 0.39%
3,503,190
– –
SNCE
49
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$7.92M 0.38%
990,412
– –
RAPT
50
DELISTED
RAPT Therapeutics
RAPT
$7.1M 0.34%
53,436
-554
-1% -$90.4K
1
2
3 4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q3 2023 Portfolio in Review

As of Q3 2023, Redmile Group held 76 positions worth $2.1B, down 19% from $2.61B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $227M in Q3 2023, closing 8 positions and reducing 26 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $42.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in RayzeBio, Inc. Common Stock worth $41.2M.

  • Redmile Group's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,857,706 shares worth $41.2M.
  • Redmile Group added most to Boston Scientific in Q3 2023, an estimated $20.1M increase.
  • Redmile Group's biggest Q3 2023 reduction was Krystal Biotech, cutting an estimated $68.7M.
  • Redmile Group fully exited BioMarin Pharmaceuticals in Q3 2023, selling an estimated $42.4M.
  • Redmile Group's ten largest holdings make up 55% of its $2.1B portfolio in Q3 2023.
  • Redmile Group opened 4 new positions and closed 8 in Q3 2023.
  • Redmile Group's portfolio value fell 19% quarter-over-quarter to $2.1B.

Based on Redmile Group's 13F filing for Q3 2023, filed 14 Nov 2023.